Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK

B C Reeves, S P Harding, J Langham, R Grieve, K Tomlin, J Walker, C Guerriero, J Carpenter, W P Patton, K A Muldrew, T Peto, U Chakravarthy

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

The verteporfin photodynamic therapy (VPDT) cohort study aimed to answer five questions: (a) is VPDT in the NHS provided as in randomised trials?; (b) is 'outcome' the same in the nhs as in randomised trials?; (c) is 'outcome' the same for patients ineligible for randomised trials?; (d) is VPDT safe when provided in the NHS?; and (e) how effective and cost-effective is VPDT?
Original languageEnglish
Pages (from-to)i-xii, 1-200
JournalHealth Technology Assessment
Volume16
Issue number6
DOIs
Publication statusPublished - 2012

Structured keywords

  • BTC (Bristol Trials Centre)

Keywords

  • Porphyrins
  • Randomized Controlled Trials as Topic
  • Humans
  • Aged
  • Macular Degeneration
  • Outcome Assessment (Health Care)
  • Great Britain
  • State Medicine
  • Registries
  • Retinal Neovascularization
  • Photosensitizing Agents
  • Aged, 80 and over
  • Cost-Benefit Analysis
  • Cohort Studies
  • Middle Aged
  • Female
  • Male

Fingerprint Dive into the research topics of 'Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK'. Together they form a unique fingerprint.

Cite this